Vernalis hit by fresh U.S. setback for cough and cold drug

Published 7y ago

Shares in Vernalis fell more than 15 percent on Monday as the British biotech company backed by fund manager Neil Woodford and his previous employer Invesco announced a fresh setback for a key new drug in the United States. More »